Abciximab FDA Link

A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. It is used in treatment of refractory unstable angina, and for prevention of ischemic complications in patients undergoing percutaneous coronary procedures such as ANGIOPLASTY; ATHERECTOMY; or stenting.

Also Known As:

ReoPro; CentoRx; Chimeric 7E3 Fab; Clotinab; c7E3 Fab; Fab, Chimeric 7E3

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Abciximab: 1218
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Abciximab: 1218
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Abciximab: 1218
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Abciximab: 1218
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Abciximab: 1218
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Abciximab: 1218
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fab Fragments: 769
        Abciximab: 1218

Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators Selected Research

Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators Research Topics

Disease

Drug/Important Bio-Agent (IBA)